Bullous Keratopathy Market Summary

• Bullous keratopathy is caused by edema of the cornea, resulting from failure of the corneal endothelium to maintain its normally transparent, dehydrated state. Most frequently, it is due to Fuchs corneal endothelial dystrophy or corneal endothelial trauma. 
• Angle-closure-related mechanisms emerged as the predominant contributors to bullous keratopathy, accounting for ~51% of cases. In contrast, aphakic and pseudophakic bullous keratopathy were concentrated among cases with missing pre-cataract surgery anterior chamber depth data, highlighting the importance of underlying anterior segment characteristics in bullous keratopathy etiology.
• Corneal endothelial cell density normally ranges between 2,500 and 3,000 cells/mm²; however, corneal decompensation and the development of bullous keratopathy generally occur when the density falls below 500–700 cells/mm².
• Pseudophakic bullous keratopathy is a common indication for corneal transplantation, accounting for approximately 25% of cases across several studies.
• Pseudophakic bullous keratopathy develops in approximately 0.1–2.0% of patients following cataract surgery, although the incidence has declined with modern surgical techniques.
• Japan’s bullous keratopathy etiology profile differs markedly from Western markets, with lens implantation-related cases accounting for a substantially larger share, while Fuchs dystrophy remains relatively uncommon.
• Standardized diagnostic and management guidelines are needed to improve disease identification and treatment consistency, while better understanding of etiology and pathogenesis could support more targeted and potentially curative therapies.
• Current treatment of bullous keratopathy is primarily aimed at controlling corneal edema and relieving symptoms. Early disease is managed with lubricants, hyperosmotic agents, topical steroids, and bandage contact lenses, while advanced disease may require endothelial keratoplasty (DMEK/DSAEK) or penetrating keratoplasty (PKP).
• There is no approved therapy except the recently approved Aurion Biotech’s neltependocel (VYZNOVA). It is only approved in Japan and is the first approved allogeneic cell therapy formulated as an intracameral injection for corneal endothelial cell regeneration.
• Current pharmacological treatments are largely symptom-relieving, while donor shortages limit access to corneal transplantation. Regenerative and tissue-engineering approaches, including TTHX1114, EO2002, CLS001, and others, are being explored to restore corneal endothelial function, although the late-stage pipeline remains limited.

 Bullous Keratopathy Market Size and Forecast in the 7MM

• 2025 Bullous Keratopathy Market Size: ~USD XX million
• 2036 Projected Bullous Keratopathy Market Size: ~USD XX million
• Bullous Keratopathy Growth Rate (2026–2036): ~XX% CAGR

DelveInsight's ‘Bullous Keratopathy– Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of bullous keratopathy, historical and forecasted epidemiology, as well as the bullous keratopathy market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Bullous Keratopathy market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Bullous Keratopathy patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis. It provides an in-depth market size assessment and growth rate projections (historical & forecast 2022–2036) across global regions. The report highlights key unmet medical needs in bullous keratopathy. It maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Bullous Keratopathy Market

Increasing prevalence of corneal endothelial disorders and ocular surgeries

The rising incidence of conditions such as Fuchs endothelial corneal dystrophy, along with the growing number of cataract and other intraocular surgeries, is contributing to a larger patient population at risk of developing bullous keratopathy.

Advancements in endothelial regenerative and cell-based therapies

The emergence of cell therapies, ROCK inhibitors, and tissue-engineered corneal endothelial treatments is shifting the treatment landscape beyond conventional corneal transplantation, offering the potential for earlier intervention and improved visual outcomes.

Growing adoption of minimally invasive corneal procedures and improved access to specialized eye care

Increased availability of advanced corneal surgical techniques, enhanced diagnostic capabilities, and greater access to corneal specialists are facilitating earlier diagnosis, timely treatment, and improved patient outcomes.

Bullous Keratopathy Understanding and Treatment Algorithm

Bullous Keratopathy Overview and Diagnosis

Bullous keratopathy is a corneal disorder characterized by corneal edema resulting from irreversible loss or dysfunction of corneal endothelial cells, leading to failure of the endothelial pump mechanism. The condition commonly develops following cataract surgery (pseudophakic bullous keratopathy), ocular trauma, Fuchs endothelial corneal dystrophy, glaucoma surgery, or other intraocular procedures. Progressive corneal edema causes epithelial bullae, blurred vision, pain, photophobia, foreign body sensation, and recurrent epithelial erosions, significantly impairing quality of life. Diagnosis is based on a comprehensive ophthalmic examination using slit-lamp biomicroscopy, supported by specular microscopy to assess endothelial cell density and morphology, corneal pachymetry to measure corneal thickness, and anterior segment optical coherence tomography (AS-OCT) to evaluate the extent of corneal edema. Early and accurate diagnosis is essential to guide appropriate management and determine the need for medical therapy or corneal transplantation.

Further details are provided in the report.

Current Bullous Keratopathy Treatment Landscape

The treatment of bullous keratopathy is primarily aimed at relieving symptoms, reducing corneal edema, and restoring visual function. Initial management includes hypertonic saline eye drops and ointments, lubricants, bandage contact lenses, topical antibiotics, and analgesics to alleviate pain and protect the corneal surface. In patients with persistent corneal edema and significant visual impairment, corneal transplantation remains the standard of care, with endothelial keratoplasty procedures such as Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) and Descemet Membrane Endothelial Keratoplasty (DMEK) increasingly preferred over penetrating keratoplasty due to faster visual recovery and lower complication rates.

Further details related to country-based variations are provided in the report.

Bullous Keratopathy Unmet Needs

The section “unmet needs of Bullous Keratopathy” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress. 

1. Limited availability of therapies that restore corneal endothelial function
2. Continued dependence on donor corneal tissue for definitive treatment
3. Persistent visual impairment and recurrent corneal pain despite supportive therapies
4. Delayed diagnosis and referral, contributing to progressive corneal damage and vision loss
5. Limited non-surgical treatment options that address the underlying disease, and others…..

Note: Comprehensive unmet needs insights in bullous keratopathy and their strategic implications are provided in the full report.

Bullous Keratopathy Epidemiology

Key Findings from Bullous Keratopathy Epidemiological Analysis and Forecast 

• Among the major etiologies of bullous keratopathy, FECD accounted for the highest number of cases, nearly 70% of the total cases in the US, followed by cataract surgery, which accounted for approximately 25%. On the contrary, those in glaucoma surgery cases were the least, at only 5% of the total cases. 
• FECD accounts for the largest share of bullous keratopathy cases (~50%), followed by cataract surgery (~10%) and glaucoma surgery (~40%).
• Bullous keratopathy demonstrates a slight female predominance, with females accounting for approximately 60% of cases compared with 40% in males. 
• In the US, ~80% of corneal transplant/keratoplasty cases are overall cases, while ~20% are attributable to bullous keratopathy.
• Bullous keratopathy predominantly affects older adults, reflecting its close association with age-related endothelial cell loss and cataract surgery.
• Approximately 30–40% of patients undergoing endothelial keratoplasty for bullous keratopathy have underlying Fuchs endothelial corneal dystrophy, highlighting it as one of the leading predisposing conditions for endothelial decompensation requiring surgical intervention.

Bullous Keratopathy Drug Analysis & Competitive Landscape

The Bullous Keratopathy drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I–III clinical trials. It covers the mechanism of action, clinical trial data, patents, collaborations, and strategic partnerships, upcoming key catalysts for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the bullous keratopathy treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the bullous keratopathy therapeutics market.

Approved Therapies for Bullous Keratopathy

Neltependocel (VYZNOVA): Aurion Biotech

It is a cell therapy indicated for treating bullous keratopathy of the cornea in Japan. VYZNOVA consists of allogeneic human corneal endothelial cells, referred to as “neltependocel”, and Y-27632, a small molecule drug that inhibits Rho-associated, coiled-coil containing protein kinase. This combination facilitates the regeneration of fully differentiated corneal endothelial cells (CECs) outside the body. Donor corneal cells undergo a proprietary, multi-step process to create off-the-shelf allogeneic CECs. These cells are injected into the eye, where they form a healthy monolayer and reduce corneal edema by removing excess fluid.

In September 2024, Aurion Biotech announced the commercial launch of neltependocel (VYZNOVA) in Japan for the treatment of bullous keratopathy. 

The Japanese Ministry of Health, Labor and Welfare (MHLW) set the official reimbursement price at 9,464,500 JPY per single-use vial, positioning it as a premium, high-margin asset in the regenerative ophthalmology sector.

Bullous Keratopathy Pipeline Analysis

EO2002: Emmecell

EO2002 is an investigational non-surgical, magnetic cell-based therapy being developed using Emmecell’s Magnetic Cell Delivery (MCD) platform. The platform uses magnetic nanoparticles to facilitate the targeted delivery and retention of therapeutic cells at the desired tissue site, with the potential to promote corneal endothelial regeneration and restore function. 

EO2002 is currently being evaluated in the Phase II EMERALD study (NCT07729137) for subjects with corneal edema secondary to corneal endothelial dysfunction, with the trial not yet recruiting.

In April 2024, Emmecell completed the final dose administration for the last patient in the US randomized, double-masked, multi-center Phase I trial assessing the safety and efficacy of EO2002 for treating corneal edema.

Note: Detailed emerging therapies assessment will be provided in the final report.

Bullous Keratopathy Drug Updates

• In July 2026, Emmecell received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for EO2002 for the treatment of corneal endothelial disease.

Bullous Keratopathy Key Players, Market Leaders and Emerging Companies

• Emmecell
• Cellusion
• Aurion Biotech, and others

Bullous Keratopathy Market Outlook

The bullous keratopathy treatment landscape is gradually shifting from symptom management and corneal transplantation toward regenerative approaches. While DMEK and DSAEK remain important options for visual rehabilitation, supportive therapies primarily provide symptomatic relief. The 2023 approval of neltependocel in Japan as the first approved allogeneic corneal endothelial cell therapy marks a key advancement in regenerative treatment and provides a potential alternative to donor-dependent transplantation. The emerging pipeline includes TTHX1114 (NM141), EO2002, and CLS001, which aim to restore endothelial function and reduce reliance on donor tissue.

However, market development remains constrained by the limited late-stage pipeline and early clinical maturity of most regenerative candidates. Uncertainty around long-term durability, manufacturing scalability, specialized administration, and reimbursement may further limit adoption. Established surgical approaches and donor tissue availability also remain important considerations for treatment selection. Continued clinical validation and successful commercialization will determine the pace at which regenerative therapies can expand beyond conventional transplantation.

Further details will be provided in the report….

Drug Class/Insights into Leading Emerging and Marketed Therapies in Bullous Keratopathy (2022-2036)

The Bullous Keratopathy pipeline comprises therapies aimed at restoring corneal endothelial function, promoting endothelial cell regeneration, reducing corneal edema, and overcoming the limitations of donor-dependent corneal transplantation. These approaches seek to improve visual acuity, accelerate corneal recovery, reduce reliance on donor corneas, minimize surgical complications, and ultimately enhance long-term clinical outcomes and quality of life for patients with bullous keratopathy.

• Fibroblast growth factor-1 (FGF-1) protein: FGF-1 is a regenerative biologic that promotes corneal endothelial cell survival, proliferation, and repair, thereby supporting restoration of endothelial function and reduction of corneal edema. TTHX1114 (NM141) utilizes FGF-1 and is being investigated as a regenerative, disease-modifying approach for bullous keratopathy and other corneal endothelial disorders, with the potential to reduce dependence on donor corneal transplantation. 
• Allogeneic/cultured corneal endothelial cell therapy: This approach replaces or supplements dysfunctional endothelial cells with cultured corneal endothelial cells, restoring the corneal endothelial pump function and reducing corneal edema. Neltependocel represents a cultured human corneal endothelial cell therapy and has been commercially launched in Japan for bullous keratopathy. EO2002 uses magnetic human corneal endothelial cells, while CLS001 comprises allogeneic iPSC-derived corneal endothelial cell substitutes designed to restore endothelial function and potentially provide an alternative to conventional donor corneal transplantation.

Bullous Keratopathy Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the bullous keratopathy drug’s uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug. 

The bullous keratopathy treatment landscape is expected to gradually evolve with the introduction of approved regenerative cell therapies alongside established surgical management during the forecast period. The adoption of neltependocel is expected to be influenced by its ability to restore corneal endothelial function, improve corneal clarity and visual outcomes, and reduce reliance on donor corneal transplantation. Uptake will also depend on physician familiarity, treatment-center capabilities, reimbursement, pricing, patient eligibility, and the availability of trained specialists for cell-based treatment.

Detailed insights into emerging therapies' drug uptake are included in the report.

Market Access and Reimbursement of Approved Therapies in Bullous Keratopathy

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc. 

NOTE: Further Details are provided in the final report….

Bullous Keratopathy Therapies Price Scenario & Trends 

Pricing and analogue assessment of bullous keratopathy therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and the understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Bullous Keratopathy

To keep up with bullous keratopathy market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on bullous keratopathy emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in bullous keratopathy, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the Hillman Cancer Center, Université Center Léon Bérard, Society of Hematology, Aichi Medical University, etc., were contacted. Their opinion helps understand and validate current and emerging bullous keratopathy therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in bullous keratopathy.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. 

In the SWOT analysis of Bullous Keratopathy Disease, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. For efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of bullous keratopathy, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the bullous keratopathy market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM bullous keratopathy market. 

Report Insights

• Bullous Keratopathy Patient Population Forecast
• Bullous Keratopathy Therapeutics Market Size 
• Bullous Keratopathy Pipeline Analysis
• Bullous Keratopathy Disease Market Size and Trends
• Bullous Keratopathy Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report 
• 11-Year Forecast 
• Bullous Keratopathy Market Outlook (North America, Europe, Asia-Pacific) 
• Patient Burden Trends (By Geography)
• Bullous Keratopathy Treatment Addressable Market (TAM)
• Bullous Keratopathy Competitive Landscape
• Bullous Keratopathy Major Companies Insights
• Bullous Keratopathy Price Trends and Analogue Assessment
• Bullous Keratopathy Therapies Drug Adoption/Uptake
• Bullous Keratopathy Therapies Peak Patient Share Analysis

Report Assessment

• Bullous Keratopathy Current Treatment Practices
• Bullous Keratopathy Unmet Needs
• Bullous Keratopathy Clinical Development Analysis
• Bullous Keratopathy Emerging Drugs Product Profiles
• Bullous Keratopathy Market Attractiveness
• Bullous Keratopathy Qualitative Analysis (SWOT and Conjoint analysis)

FAQs

Market Insights

• What was the bullous keratopathy market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of bullous keratopathy?
• What are the disease risks, burdens, and unmet needs of bullous keratopathy? What will be the growth opportunities across the 7MM concerning the patient population with bullous keratopathy?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of bullous keratopathy? What are the current guidelines for treating bullous keratopathy in the US, Europe, and Japan?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the bullous keratopathy market.
• Bottom‑up forecasting builds from the affected population to product forecasts, delivering a robust, data‑driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatments to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)‑enabled report summarizes and simplifies complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data‑driven decisions.